ERBB2 and breast cancer: T-DM1 + P was also assessed in patients with HER2-positive stage II/III breast cancer in KRISTINE, a phase III study that compared neoadjuvant T-DM1 + P with docetaxel, carboplatin, and trastuzumab plus pertuzumab (TCH + P) [10, 11].